Skip to Content

Silverback Therapeutics, Inc.

Securities Class Action

  • Date:
  • 1/4/2022
  • Company Name:
  • Silverback Therapeutics, Inc.
  • Stock Symbol:
  • SBTX
  • Class Period:
  • FROM 12/3/2020 TO 9/10/2021
  • Status:
  • Filed
  • Court:
  • U.S. District Court: Disrtict of Western Washington

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Silverback Therapeutics, Inc. (“Silverback” or the “Company”) (NASDAQ: SBTX) in the United States District Court for the Western District of Washington on behalf of all persons and entities who purchased or otherwise acquired Silverback securities between December 3, 2020 and September 10, 2021, both dates inclusive (the “Class Period”) and/or pursuant to the December 3, 2020 IPO. Investors have until January 4, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the filed complaint, (i) Silverback's lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.


If you purchased or otherwise acquired Silverback shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by filling out the form below. There is no cost or obligation to you.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Silverback Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: